Literature DB >> 22197609

Salting-out homogeneous liquid-liquid extraction approach applied in sample pre-processing for the quantitative determination of entecavir in human plasma by LC-MS.

Feng-Juan Zhao1, Hong Tang, Qing-Hua Zhang, Jin Yang, Andrew K Davey, Ji-Ping Wang.   

Abstract

A convenient, robust, economical and selective sample preparation method for the quantitative determination of entecavir in human plasma by LC-MS was developed and validated. Entecavir and the internal standard of acyclovir were extracted from 500 μL of human plasma by a salting-out homogeneous liquid-liquid extraction approach (SHLLE) with acetonitrile as the organic extractant and magnesium sulfate as the salting-out reagent. They were analyzed on a Hanbon® Lichrospher RP C18 HPLC column (150 mm×2.0 mm; 5 μm) with gradient elution. The mobile phase comprised 0.1% acetic acid-0.2 mmol ammonium acetate in water (mobile phase A) and acetonitrile (mobile phase B). The flow rate is 0.2 mL/min. The analytes were detected by a LC-MS 2010 single quadrupole mass spectrometer instrument equipped with an electrospray ionization interface using selective ion monitoring positive mode. A "post cut" column switch technique was incorporated into the method to remove interferences of earlier and later eluting matrix components than entecavir and internal standard, including salting-out reagent used in sample pre-processing. The method was validated over the concentration range of 0.05-20 ng/mL. The intra-day and inter-day precision of the assay, as measured by the coefficient of variation (%CV), was within 3.59%, and the intra-day assay accuracy was found to be within 4.88%. The average recovery of entecavir was about 50% and the ion suppression was approximately 44% over the standard curve. Comparison of matrix effect between SHLLE and SPE by continuous post column infusion showed that these two methods got similar, slight ion suppression. The SHLLE method has been successfully utilized for the analysis of entecavir in post-dose samples from a clinical study. Crown
Copyright © 2011. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22197609     DOI: 10.1016/j.jchromb.2011.12.003

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  2 in total

1.  Involvement of multidrug resistance protein 4 in the hepatocyte efflux of lamivudine and entecavir.

Authors:  Yu-Tian Liu; Wei Liu; Gang-Yan Zhu; Fu-Liang Wang; Qian Chen
Journal:  Mol Med Rep       Date:  2018-03-19       Impact factor: 2.952

2.  Effects of Fuzheng Huayu recipe on entecavir pharmacokinetics in normal and dimethylnitrosamine-induced hepatic fibrosis rats.

Authors:  Tao Yang; Tian-Hui Zheng; Qiang Zhao; Wei Liu; Shu-Ping Li; Yan-Yan Tao; Chang-Hong Wang; Cheng-Hai Liu
Journal:  Pharm Biol       Date:  2020-12       Impact factor: 3.503

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.